Top Markets
#1 ADO Protocol ADO Protocol +328.31%
#2 GoPlus Security GoPlus Security +53.48%
#3 Starpower Starpower +39.21%
#4 Verus Coin Verus Coin +33.62%
#5 Tutorial Tutorial +32.14%
#6 Nockchain Nockchain +31.86%
#7 Chainflip Chainflip +28.58%
#8 The Black Bull The Black Bull +27.70%
#9 GAIB AID GAIB AID +24.67%
#10 peaq peaq +18.42%
Coin of the day
ADO Protocol ADO Protocol
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
NuCana plc NuCana plc

NuCana plc

NCNA
Classement en actions #32773
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Prix de l'action
$1.51
Capitalisation boursière
$9.14M
Changement (1 jour)
-5.35%
Changement (1 an)
-59.65%
Pays
GB
Échange NuCana plc (NCNA)

Catégorie

Healthcare
Revenus pour NuCana plc (NCNA)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de NuCana plc, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour NuCana plc de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE